Vertex Pharmaceuticals Incorporated Earnings Recaps
Q1 2026
May 5, 2026
Vertex's Q1 results were largely in line with expectations, reflected in a flat market reaction of +0.1%. Despite solid revenue growth and progress across multiple franchises, the stock's muted response suggests investors found limited reasons for enthusiasm beyond steady execution.
Key takeaways
- Total product revenue reached $2.99 billion, marking 8% year-over-year growth.
- Products in new disease areas, including KASJEVY and GERNAVICS, contributed about 25% of total product revenue growth.
- Commercial milestones include AlifTrack surpassing $1 billion in cumulative revenue and over 500 patients starting KASJEVY treatment.
- R&D progress featured rapid regulatory submissions for POBI in IgAN and KASJEVY in pediatric sickle cell disease/beta thalassemia, with clinical trials advancing across various indications.
- VX-522 mRNA therapy program was discontinued due to tolerability issues, eliminating potential upside from this next-generation CF treatment.
Q3 2025
Nov 4, 2025
Vertex Pharmaceuticals reported a strong Q3 2025 performance with revenues of $3.08 billion, driven by robust growth in cystic fibrosis treatments and advancements in its renal disease pipeline.
Key takeaways
- Achieved revenue of $3.08 billion, representing double-digit growth year-over-year.
- Continued strong uptake of ALYFTREK, qualifying 95% of CF patients for treatment, with significant clinical improvements reported.
- Progressing towards regulatory submissions for TRIKAFTA for ages 1-2, demonstrating unprecedented reductions in sweat chloride levels.
- Promising developments in the kidney portfolio, including initiation of Phase II studies for VX-407 and inaxaplin targeting serious renal diseases.
- Successful Phase IV trials for JOURNAVX in acute pain management indicate significant reductions in opioid use post-surgery.